Perioperative Treatment of Resectable Liver Metastases (PERIMAX)
This randomized, controlled, multicenter, non-comparative phase II trial compares an intensified perioperative treatment of patients with resectable synchronous or metachronous colorectal liver metastases to primary surgery and adjuvant systemic chemotherapy.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Perioperative FOLFOXIRI and Bevacizumab Compared With Postoperative FOLFOX in Patients With Resectable Liver Metastases From Colorectal Cancer (PERIMAX). A Randomized, Multidisciplinary DGAV(CAO-V/CALGP)/AIO Phase II Trial|
- Failure-free survival (FFS@18) [ Time Frame: 18 months ] [ Designated as safety issue: No ]Failure will be defined as no R0 resection, local or distant recurrence or death from any cause.
- Disease Free Survival (DFS) [ Time Frame: 5 years ] [ Designated as safety issue: No ]
- Overall survival (OS) [ Time Frame: 5 years ] [ Designated as safety issue: No ]
- Perioperative morbidity [ Time Frame: 30 days (hospital stay) ] [ Designated as safety issue: Yes ]
- Quality of life [ Time Frame: 12 months ] [ Designated as safety issue: No ]
- Achievability of R0 resection [ Time Frame: intraoperative ] [ Designated as safety issue: No ]
- Overall response rate (Arm B) [ Time Frame: 3 months ] [ Designated as safety issue: No ]
- Pathologic response rate [ Time Frame: 18 weeks ] [ Designated as safety issue: No ]
|Study Start Date:||September 2012|
|Estimated Study Completion Date:||October 2018|
|Estimated Primary Completion Date:||October 2015 (Final data collection date for primary outcome measure)|
No Intervention: Postoperative Arm (Arm A)
Oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/m2 iv over 48 hours (day 1-3)
Duration of treatment:
Treatment will be administered for 12 cycles (6 months) postoperatively starting 6 weeks after surgery.
Experimental: Perioperative Arm (Arm B)
Therapy will be administered in a biweekly schedule. First preoperative cycle will be administered with 75% of dosage for FOLFOXIRI, if no diarrhea ≥ grade 3 occurs, following cycles should be administered in full dosage.
FOLFOXIRI + bevacizumab:
bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) irinotecan at a dose of 165 mg/m2 iv over two hours (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/m2 iv over 48 hours (day 1-3)
Duration of treatment:
Treatment will be administered for 6 cycles (3 months) preoperatively (last cycle without bevacizumab), after 6 weeks followed by liver surgery, after further 6 weeks followed by 6 cycles (3 months) postoperatively.
Bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) + FOLFOXIRI in a biweekly schedule, 6 cycles preoperatively, 6 cycles postoperatively
Other Name: VEGF antibody
Recurrence rates after R0-resection of colorectal liver metastases are still very high (about 60-70 %). Therefore, multidisciplinary treatment of these patients is frequently used in order to achieve a beneficial impact regarding progression-free and overall survival. The point in time of treatment, pre- and/or postoperative, is still a matter of debate. In the EORTC 40983 trial, perioperative chemotherapy with 5-Fluorouracil and oxaliplatin (FOLFOX-Regimen) displayed a non-significant benefit in 3 year disease free survival in the intent to treat population (HR 0.79, 95% CI 0.62 to 1.02) (Nordlinger, Sorbye et al. 2008). The combined analysis of two adjuvant trials, with a (non-contemporary) 5-FU Bolus regimen, showed a non-significant prolongation of median disease free survival (DFS) from 18.8 to 27.9 months (p=0.058) and OS from 47.3 to 62.2 months (p=0.095) (Mitry, Fields et al. 2008). However, postoperative treatment with 6 months of FOLFOX is often used in daily practise. Thus, further investigation is urgently warranted.
This phase II trial evaluates two strategies with intensified perioperative or postoperative treatment regimens. Current studies established the role of the FOLFOXIRI regimen in the metastatic setting (Falcone, Ricci et al. 2007). A further intensification of a three drug regimen with bevacizumab seem to be feasible yielding response rates up to 84% and a disease control rate up to 100% (Falcone 2008; Bruera, Santomaggio et al. 2010; Masi, Loupakis et al. 2010). Regarding the efficacy, evaluation of FOLFOXIRI and bevacizumab in preoperative treatment for resectable CLM seems to be promising. Postoperative treatment with FOLFOX for 6 months was chosen for arm A.
|Contact: Hans J. Schlitt, Prof. MD||0049 941 944 ext email@example.com|
|Contact: Hans J. Schmoll, Prof. MD||0049 345 557 ext firstname.lastname@example.org|
|University Medical Center Regensburg||Recruiting|
|Regensburg, Germany, 93042|
|Contact: Hans J. Schlitt, Prof. MD 0049 941 944 ext 6801 email@example.com|
|Contact: Gabriel Glockzin, MD 0049 941 944 ext 0 firstname.lastname@example.org|
|Study Chair:||Hans J. Schlitt, Prof. MD||Department of Surgery, University Medical Center Regensburg|
|Study Director:||Hans-Joachim Schmoll, Prof. MD||Department of Internal Medicine IV, University Hospital Halle|